This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

16 Nov 2011

More than $350M Invested by Boehringer Ingelheim for U.S. Projects This Year

Boehringer Ingelheim has invested over $350 million in its U.S. operations this year to enhance its drug discovery, development and manufacturing capabilities.

German pharma giant Boehringer Ingelheim has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.


The latest investment is a 72,000 square-foot research and development facility at the company's U.S. headquarters in Ridgefield, Connecticut. When complete the $65 million facility will handle production of active pharmaceutical ingredients used in early development activities. Products developed here, if approved, move on to Boehringer Ingelheim's full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.


Other investment announcements by Boehringer Ingelheim in 2011

Related News